FibroGen Inc (NAS:FGEN)
$ 1.155 -0.035 (-2.94%) Market Cap: 114.89 Mil Enterprise Value: 89.74 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

Q4 2022 FibroGen Inc Earnings Call Transcript

Feb 27, 2023 / 10:00PM GMT
Release Date Price: $22.51 (+1.35%)
Operator

Thank you for standing by, and welcome to FibroGen's Fourth Quarter and Full Year 2022 Financial Results Earnings Call. (Operator Instructions)

I would now like to hand the call over to your host, Mike Tung. Please, go ahead.

Michael Tung

Thank you, Latif, and good afternoon, everyone. I'm Michael Tung, Vice President of Corporate Strategy and Investor Relations at FibroGen. Joining me on today's call are Enrique Conterno, our Chief Executive Officer; Dr. Mark Eisner, our Chief Medical Officer; Juan Graham, our Chief Financial Officer; Dr. John Hunter, our Chief Scientific Officer; Thane Wettig, our Chief Commercial Officer; and Chris Chung, our Senior Vice President of China Operations. The format for today's call includes prepared remarks from Enrique and Juan, after which, we will open up the call for Q&A.

I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, our collaborations with AstraZeneca and Astellas, financial guidance, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot